Lending further validity to this approach, two HGF-based agents are being studied in clinical trials for use in patients with ALS: an HGF plasmid given through a series of intramuscular injections and a recombinant HGF protein injected intrathecally (Sufit et al., 2017; Warita et al., 2019). This evidence concerns the gene HGF and amyotrophic lateral sclerosis.